Integrated proteogenomic characterization of glioblastoma evolution
Cancer Cell · 2024-03 · 42 (3) · 358-377.e8
DOI: 10.1016/j.ccell.2023.12.015 ↗Kurz gefasst
Kommentar in der Zeitschrift Cancer Cell, 2024-03. Verfasst von Kyung-Hee Kim und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea; Proteomics Core Facilit…. Hauptthemen laut MEDLINE: Glioblastoma, Proteogenomics, Brain Neoplasms. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Center, Korea Evaluation Institute of Industrial Technology.
Abstract (Originalsprache)
The evolutionary trajectory of glioblastoma (GBM) is a multifaceted biological process that extends beyond genetic alterations alone. Here, we perform an integrative proteogenomic analysis of 123 longitudinal glioblastoma pairs and identify a highly proliferative cellular state at diagnosis and replacement by activation of neuronal transition and synaptogenic pathways in recurrent tumors. Proteomic and phosphoproteomic analyses reveal that the molecular transition to neuronal state at recurrence is marked by post-translational activation of the wingless-related integration site (WNT)/ planar cell polarity (PCP) signaling pathway and BRAF protein kinase. Consistently, multi-omic analysis of patient-derived xenograft (PDX) models mirror similar patterns of evolutionary trajectory. Inhibition of B-raf proto-oncogene (BRAF) kinase impairs both neuronal transition and migration capability of recurrent tumor cells, phenotypic hallmarks of post-therapy progression. Combinatorial treatment of temozolomide (TMZ) with BRAF inhibitor, vemurafenib, significantly extends the survival of PDX models. This study provides comprehensive insights into the biological mechanisms of glioblastoma evolution and treatment resistance, highlighting promising therapeutic strategies for clinical intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea; Proteomics Core Facility, Research Core Center, Research Institute, National Cancer Center, G…
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
- Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea; Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea; Dep…
- Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
- Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea; Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
- Laboratory of Neuroscience, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, Korea.
Förderung
- NCI NIH HHS
- National Cancer Center
- Korea Evaluation Institute of Industrial Technology
- National Research Foundation of Korea
- National Institutes of Health
- Institut National Du Cancer
- National Cancer Institute
- Ministry of Science, ICT and Future Planning
Zitieren
APA
Kim, K. H., Migliozzi, S., Koo, H., Hong, J. H., Park, S. M., Kim, S., Kwon, H. J., Ha, S., Garofano, L., Oh, Y. T., D'Angelo, F., Kim, C. I., Kim, S., Lee, J. Y., Kim, J., Hong, J., Jang, E. H., Mathon, B., Di Stefano, A. L., …, & Park, J. B. (2024). Integrated proteogenomic characterization of glioblastoma evolution. Cancer Cell, 42(3), 358-377.e8. https://doi.org/10.1016/j.ccell.2023.12.015
Vancouver
Kim KH, Migliozzi S, Koo H, Hong JH, Park SM, Kim S, et al. Integrated proteogenomic characterization of glioblastoma evolution. Cancer Cell. 2024;42(3):358-377.e8. doi:10.1016/j.ccell.2023.12.015
BibTeX
@article{Kim2024,
author = {Kim, Kyung-Hee and Migliozzi, Simona and Koo, Harim and Hong, Jun-Hee and Park, Seung Min and Kim, Sooheon and Kwon, Hyung Joon and Ha, Seokjun and Garofano, Luciano and Oh, Young Taek and D'Angelo, Fulvio and Kim, Chan Il and Kim, Seongsoo and Lee, Ji Yoon and Kim, Jiwon and Hong, Jisoo and Jang, Eun-Hae and Mathon, Bertrand and Di Stefano, Anna-Luisa and Bielle, Franck and Laurenge, Alice and Nesvizhskii, Alexey I and Hur, Eun-Mi and Yin, Jinlong and Shi, Bingyang and Kim, Youngwook and Moon, Kyung-Sub and Kwon, Jeong Taik and Lee, Shin Heon and Lee, Seung Hoon and Gwak, Ho Shin and Lasorella, Anna and Yoo, Heon and Sanson, Marc and Sa, Jason K and Park, Chul-Kee and Nam, Do-Hyun and Iavarone, Antonio and Park, Jong Bae},
title = {Integrated proteogenomic characterization of glioblastoma evolution},
journal = {Cancer Cell},
year = {2024},
volume = {42},
number = {3},
pages = {358--377.e8},
doi = {10.1016/j.ccell.2023.12.015}
}
EUVIMED